Satellite Symposium «New Possibilities for Correcting Focal Epilepsy Therapy»

On February 16, 2022, the satellite symposium «New opportunities for correction of focal epilepsy therapy» was held at the Interregional Scientific and Practical Conference «Epilepsy and paroxysmal states as an interdisciplinary problem». The main topic of symposium was the first year data of experience of using Dibufelon® for the treatment of focal forms of epilepsy. Neurobiologists, psychopharmacologists and practicing epileptologists took part at the event.

Professor Karlov V.A., the President of the Anti-Epileptic League, one of the founders of Soviet and Russian epileptology attended.

Professor Gulyaeva N.V., the Head of the Laboratory of functional biochemistry of the nervous system of the Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences and neurologist Yakovleva A.A., a young scientific researcher of the laboratory of psychopharmacology of the Research Institute of Pharmacology demonstrated the new scientific data about the mechanisms of Dibufelon® action.

The main researchers of the Russian Observation Program Professor Burd S.G. and Professor Lebedeva A.V. presented data on the inclusion of patients in the All-Russian Non-Intervention Observation Program «BEGINNING», designed to carefully study the asthenic status and quality of life of patients on epilepsy polytherapy.

The clinical experience of using the drug Dibufelon® collected for the first year of sales was shared by neurologist, epileptologist, Candidate of Medical Sciences from Volgograd O.V. Belyaev, the Chief Medical Officer of the Medical Center for Neurology, Diagnosis and Treatment of Epilepsy, EpiCenter LLC.

The symposium was attended by 710 neurologists, more than 1000 questions from doctors were registered. Professor Voronina T.A., the Head of the Laboratory of Psychopharmacology of the Research Institute of Pharmacology named after V.V. Zakusova answered the questions of doctors about the advantages of Dibufelon® over the existing therapy and announced a new scientific work.